Women with cosmetic breast implants do not appear to have a higher-than-average risk of any cancer years after having the surgery, a new study finds.

Researchers found that among more than 6,200 Swedish and Danish women who’d received breast implants, the long-term risk of developing breast cancer was lower than the norm, while the risks of other cancers were neither higher nor lower than average.

The results, published in the International Journal of Cancer, add to evidence that silicone-gel breast implants pose no significant cancer risk to women.

Unlike most previous studies, the current one was able to follow women beyond 15 years – with more than half of study participants tracked for at least 15 years and 13 per cent for at least 25 years.

It is the only published study to have followed breast-implant recipients that long, note the researchers, led by Loren Lipworth of the International Epidemiology Institute in Rockville, Maryland.

Because of this, the researchers write, “we were able to present for the first time risk estimates for many cancer types with high statistical precision.”

The link between breast implants and a lower risk of breast cancer has been seen in past studies as well. Researchers suspect that several factors may explain this.

Compared with other women, for example, women who undergo breast augmentation tend to be thinner and have children at a younger age – both of which may lower breast cancer risk. It’s also possible that women with a family history of breast cancer are less likely to get implants.

Dr Lipworth’s team found that only one cancer – lung cancer – occurred at a higher-than-average rate among implant recipients. That, however, appeared to be explained by their relatively high rate of smoking.

Reuters Health

Source: International Journal of Cancer, January 15, 2009

Sign up to our free newsletters

Get the best updates straight to your inbox:
Please select at least one mailing list.

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.